Precision Medicine in Parkinson’s Disease: From Genetic Risk Signals to Personalized Therapy
Understanding the pathophysiology and genetic background of Parkinson’s disease (PD) increases the likelihood of developing effective disease-modifying therapeutic strategies. In particular, the discovery of genetic variants causing or increasing the risk for PD has contributed to refining the clini...
Main Authors: | Giulia Straccia, Fabiana Colucci, Roberto Eleopra, Roberto Cilia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-09-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/12/10/1308 |
Similar Items
-
The Genetic Landscape of Sleep Disorders in Parkinson’s Disease
by: Kallirhoe Kalinderi, et al.
Published: (2024-01-01) -
Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
by: Francesco Cavallieri, et al.
Published: (2023-02-01) -
Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland
by: Diana A. Olszewska, et al.
Published: (2020-06-01) -
Neurosteroid Levels in GBA Mutated and Non-Mutated Parkinson’s Disease: A Possible Factor Influencing Clinical Phenotype?
by: Francesco Cavallieri, et al.
Published: (2024-08-01) -
Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation
by: O. Siemeling, et al.
Published: (2024-05-01)